Hôpital Bichat Claude-Bernard AP-HP
- Address
- 46 Rue Henri Huchard, cedex Paris 18, 75877 Paris, France
Hôpital Bichat Claude-Bernard AP-HP
Hôpital Bichat Claude-Bernard AP-HP is a distinguished academic medical center conducting cutting-edge clinical research across multiple therapeutic domains. The institution demonstrates particular expertise in infectious diseases, cardiovascular medicine, oncology, and autoimmune disorders, with a strong emphasis on innovative treatment strategies and personalized patient care approaches.
- HIV/AIDS and viral hepatitis research, including novel dual antiretroviral therapies and HIV-HBV co-infection management
- Cardiovascular interventions with focus on acute coronary syndromes and STEMI treatment protocols
- Immunology and nephrology studies, particularly ANCA-associated vasculitis and end-stage renal disease
- Oncological research in non-muscle invasive bladder cancer with immunotherapy combinations
The center's research portfolio reflects a commitment to addressing complex medical challenges through randomized controlled trials and multicenter collaborative studies. Their investigations span from pre-hospital emergency interventions to long-term immunosuppression management, consistently evaluating both efficacy and safety outcomes. The institution's participation in international trials, including pandemic response studies and novel biologic therapies, underscores its role as a leading European research center dedicated to advancing evidence-based medicine and improving patient outcomes across diverse clinical populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hôpital Bichat Claude-Bernard AP-HP
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Namilumab in Patients with Chronic Pulmonary Sarcoidosis: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study | Kinevant Sciences GmbH | Phase II | Not Recruiting | Nov 2022 | Mar 2025 |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Prednisolone | 2 | Unknown | 2018-02-02 | 2024-02-29 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.